G., Li, F
Back to Journals Drug Design, Development and Therapy Volume 20 GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation Received 1 April 2026 Accepted for publication 2 June 2026 Published 12 June 2026 Volume 2026:20 613616 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Professor Anastasios Lymperopoulos Pengpeng Li, Yangyang Gao, Wei Liu Department of Neurosurgery, Xian Aerospace Hospital of Northwest University, Xian, Shanxi, 710000, Peoples Republic of China Correspondence: Pengpeng Li, Email [email protected] Wei Liu, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity
The peptide consists of 15 amino acids and is notable for its stability and activity in both localized and systemic contexts
113,114 Early stages of CAN may be asymptomatic and detectable only through reduced heart rate variability (HRV) during deep breathing
These symptoms could potentially lead to dehydration, which may affect renal functionparticularly relevant for DOACs that have renal elimination pathways
Do not hesitate to seek advice halitosis is a recognised clinical concern and healthcare professionals are well placed to help
